Parasite | Eso | Sto | Cancer | ESD
[Eosinophilic esophagitis. È£»ê±¸ ½Äµµ¿°] - ðû
2021-9-28 ½Äµµ¿Í À§´ëÀåÁúȯ ³»½Ã°æ ¾ÆƲ¶ó½º Åä·Ðȸ
2021 ¼øõ¸¸³»½Ã°æ¼¼¹Ì³ª ¹ÚÈ¿Áø ±³¼ö´Ô
2023-1-10 KSGE webinar ±è°¡Èñ ±³¼ö´Ô. Log-in é©
1. ¿ªÇÐ
2. Áõ»ó
3. Áø´Ü
4. ³»½Ã°æ ¼Ò°ß
6. PPI-REE - ÀÌ¹Ì ¾È ¾²´Â Áø´Ü¸íÀÔ´Ï´Ù. EoEÀÇ subtypeÀÏ »ÓÀÔ´Ï´Ù. ´õ ÀÌ»ó »ç¿ëÇÏÁö ¸¿½Ã´Ù.
7. Ä¡·á
8. FAQ -¹«Áõ»ó È£»ê±¸ ½Äµµ¿° asymptomatic eosinophilic esophagitis
9. References
È£»ê±¸ ½Äµµ¿°Àº Áõ°¡ÇÏ°í ÀÖ´ÂÁö, ´ÜÁö Áø´Ü¸¸ ¸¹¾ÆÁö°í ÀÖ´ÂÁö ¸íÈ®ÇÏÁö ¾Ê½À´Ï´Ù (Dellon. Gastroenterology 2018). ³²³àºñ´Â ¾î´À ³ª¶ó ¾î´À ¿¬±¸¿¡¼µµ 3:1ÀÔ´Ï´Ù.
Ç︮ÄÚ¹ÚÅÍ¿Í EoE°¡ ¿ª»ó°ü °ü°è°¡ ÀÖ´Ù°í ÇÕ´Ï´Ù. ±âÀüÀº Ç︮ÄÚ¹ÚÅÍ°¡ Th1 response¸¦ ÀÏÀ¸Å°´Âµ¥ ÀÌ°ÍÀÌ Th2 response related allergic disease¸¦ ¾ïÁ¦ÇÏ´Â ±â´ÉÀÌ ÀÖÁö ¾ÊÀ»±î ÃßÁ¤µË´Ï´Ù. ±×·¯³ª »ó°ü°ü°è°¡ ¾ø´Ù´Â Spain ´Ù±â°ü ¿¬±¸(Molina-Infante. AJG 2018)µµ ÀÖ½À´Ï´Ù. ÃÖ±Ù¿¡´Â »ó°ü°ü°è°¡ ¾ø´Â ÂÊÀ¸·Î ÀÇ°ßÀÌ ¸ð¾ÆÁö°í ÀÖ½À´Ï´Ù.
ÇÑ ½ÉÆ÷Áö¾ö¿¡¼ º» ½½¶óÀ̵åÀÔ´Ï´Ù. È£»ê±¸ ½Äµµ¿°ÀÌ Á¤¸» Áõ°¡ÇÏ°í ÀÖ´Â °ÍÀÎÁö, ±×³É °ü½ÉÀÇ Áõ°¡ÀÏ »ÓÀÎÁö È®½ÅÀÌ ¼Áú ¾Ê½À´Ï´Ù.
Inflammatory phase¸¦ Áö³ª fibrotic phase·Î ³Ñ¾î°£´Ù°í ÇÕ´Ï´Ù. ¼Ò¾Æ´Â inflammatory phase¿¡ ¹ß°ßµÇ´Â °æ¿ì°¡ ¸¹°í, ¼ºÀÎÀº fibrotic phase¿¡¼ ¹ß°ßµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.
Dysphagia ȯÀÚ Áß ³»½Ã°æ¿¡¼ Ưº°ÇÑ ¼Ò°ßÀÌ ¾ø¾îµµ Á¶Á÷°Ë»ç¸¦ Çϸé È£»ê±¸ ½Äµµ¿°ÀÌ Áø´ÜµÉ ¼ö ÀÖ½À´Ï´Ù. ¾Æ·¡ ±×¸²Àº À¯·´ÀÇ ÀÇ°ßÀä, Á¶±Ý Áö³ªÄ¡´Ù ½ÍÁö¸¸ ¾Ë°í °è½Ã¸é ÁÁ°Ú½À´Ï´Ù.
Á¶Á÷°Ë»ç¿¡¼ eosinophilia°¡ high power field ´ç 15°³ ÀÌ»óÀÎ °ÍÀÌ °¡Àå Áß¿äÇÑ ±âÁØÀÔ´Ï´Ù. Á¤»ó ±âÁØÀº 5°³ ÀÌÇÏÀÔ´Ï´Ù. µå¹°°Ô 10°³±îÁö Á¤»óÀ¸·Î °£ÁÖÇÏ´Â Àü¹®°¡µµ ÀÖ½À´Ï´Ù.
Á¶Á÷°Ë»ç °¹¼ö¿¡ ´ëÇÑ consensus´Â ¾ø½À´Ï´Ù¸¸, 4°³ (»óºÎ¿¡¼ 2°³, ÇϺο¡¼ 2°³) Á¤µµ ½ÃÇàÇϸé Áø´Ü sensitivity°¡ plateau°¡ µÈ´Ù°í ÇÕ´Ï´Ù.
ÇöÀç±îÁö Áø´ÜµÈ EoE ȯÀÚÀÇ 80-90%¿¡¼´Â ³»½Ã°æÀû ÀÌ»ó ¼Ò°ßÀÌ ÀÖÁö¸¸, 10-20%¿¡¼´Â À°¾È¼Ò°ßÀÌ ¶Ñ·ÇÇÏÁö ¾ÊÀºµ¥ Áõ»ó ±â¹ÝÀ¸·Î °Ë»ç¸¦ ½ÃÇàÇÏ¿© blind biopsy ÇÑ °÷¿¡¼ EoE°¡ Áø´ÜµÈ °æ¿ìÀÔ´Ï´Ù.
½Äµµ¿¡ ±¹ÇÑµÈ °æ¿ì¸¸À» EoE·Î ºÎ¸£°í ÀÖ½À´Ï´Ù. Eosinophilic gastroenteritis°¡ ÀÖÀ¸¸é¼ ½ÄµµÀÇ È£»ê±¸ ħÀ±ÀÌ ÀÖ´Â °æ¿ì´Â EoE·Î ºÎ¸£Áö ¸»µµ·Ï Á¤ÀÇÇÏ°í ÀÖ½À´Ï´Ù. ¾Æ·¡ Áø´Ü±âÁØ¿¡ "Secondary cause of eosinophilia excluded."·Î ¸í½ÃµÈ ºÎºÐÀÔ´Ï´Ù.
[2018-5-15. ÀÌdz·Ä ±³¼ö´Ô comment]
Á¶Á÷°Ë»ç¿¡¼ Çѵΰ³ÀÇ eosinophilÀÌ ÀÖ´Ù°í Áø´ÜÀ» ºÙÀÌ¸é °ï¶õÇÕ´Ï´Ù. ºñƯÀÌÀûÀ¸·Î ¸î °³ÀÇ È£»ê±¸°¡ ÀÖÀ» °¡´É¼ºÀÌ ³ô±â ¶§¹®ÀÔ´Ï´Ù. 15°³ ±âÁØÀ» ÁöÅ°±â ¹Ù¶ø´Ï´Ù.
È£»ê±¸ ½Äµµ¿° ³»½Ã°æ ¼Ò°ß |
1) Stacked circular rings ("feline" esophagus)
2) Stricture (particularly proximal stricture) 3) Attenuation of the submucosal vascular pattern 4) Liner furrowing that may extend length of the esophagus 5) White papules (representing eosinophilic microabscess) 6) Small caliber esophagus |
´ëÇѼÒȱâÇÐȸÁö 2010;56:285-292
Evan S. Dellon (Endoscopy 2014)
Furrow³ª ringÀº ¶Ñ·ÇÇÏÁö ¾ÊÀ¸³ª white papuleµéÀÌ linearÇÏ°Ô ºÐÆ÷ÇÏ¿´´ø °æ¿ì (¾Æ·¡´Â Á¶Á÷°Ë»ç)
Representative endoscopic images suspicious of EoE. a Linear furrows. b Rings including ringed esophagus (left) and corrugated esophagus (right). c Whitish exudate. d Reddening.(Shimura. Digestion 2014)
EoE vs GERD (Hori K. Digest Endosc 2014)
PPI ȤÀº fluticasone inhaler »ç¿ë ÈÄ È£ÀüµÈ ¸ð½À (´ëÇѼÒȱâÇÐȸÁö 2010;56:285-292)
Ä¡·á ÈÄ¿¡´Â longitudinal furrow´Â healingÀÌ µÇ´Âµ¥ circular ringÀº ±×´ë·ÎÀÎ °æ¿ì°¡ ¸¹´Ù°í ÇÕ´Ï´Ù. Fixed circular ringÀº ÀÌ¹Ì fibrotic stageÀ̱⠶§¹®ÀÎ °Í °°½À´Ï´Ù.
2016³â 1¿ùÈ£ Gastrointestinal EndoscopyÁö¿¡ 'esophageal biopsy pull sign'ÀÌ ¼Ò°³µÇ¾ú½À´Ï´Ù (Dellon ES. GIE 2016). "Esophageal biopsy specimens from patients with eosinophilic esophagitis (EoE) can feel firm, with resistance felt when pulling the forceps to obtain the tissue sample." °ú¿¬ ´À³¦À̶ó´Â ÁÖ°üÀûÀÎ ºÎºÐÀ» °´°üÈÇÒ ¼ö ÀÖÀ»±î¿ä?
ÀúÀÚµéÀº pull signÀ» 'potential proxy indicator for remodeling process'À¸·Î ¼³¸íÇÏ°í ÀÖ½À´Ï´Ù. ¿©ÇÏÆ° Á¶±Ý ´Ü´ÜÇÏ°í Áú±ä ´À³¦ÀÌ µå´Â ¸ð¾çÀÔ´Ï´Ù.
[2016-8-2. Webseminar ¹Î¾ç¿ø ±³¼ö´Ô °ÀÇ Áß]
[2021-10-14] RingÀ̳ª furrow°¡ ¾ø´Â ÇüÅÂÀÇ È£»ê±¸ ½Äµµ¿°ÀÌ ÀÖ½À´Ï´Ù. 2021³â 10¿ù À̼±¿µ ±³¼ö´ÔÀÇ ±³À°ÀÚ·á¿¡¼ ¿Å±é´Ï´Ù.
È£»ê±¸ ½Äµµ¿° ³»½Ã°æ ¼Ò°ß Áß À¯¸íÇÑ °ÍÀÌ ringÀÔ´Ï´Ù. Stacked circular rings ("feline" esophagus)À̶ó°í ºÎ¸¨´Ï´Ù. ±×·±µ¥ È£»ê±¸ ½Äµµ¿°ÀÇ Áõ»óÀÌ ¾ø´Â »ç¶÷¿¡¼ ¿ì¿¬È÷ ÀϽÃÀûÀ¸·Î ringÀÌ º¸ÀÏ ¼ö ÀÖ½À´Ï´Ù. ¾Æ·¡ »çÁøÀ» º¸½Ã±â ¹Ù¶ø´Ï´Ù. ¿ì¿¬È÷ ringÀÌ º¸¿´´Âµ¥ ¸î ½Ê ÃÊ ±â´Ù·È´õ´Ï ÀúÀý·Î ÁÁ¾ÆÁ³½À´Ï´Ù. (³»½Ã°æ »çÁø ÁÂÃø ½Ã°£ ÂüÁ¶)
EoEÀÇ circular ring¿¡´Â °ÅÀÇ Ç×»ó longitudinal furrow°¡ µ¿¹ÝµË´Ï´Ù. ³»½Ã°æ °Ë»ç µµÁß ÀϽÃÀûÀÎ circular ring¿¡¼´Â longitudinal furrow°¡ ¾ø½À´Ï´Ù.
5. ³»½Ã°æ scoring (Adjusted EREFS)
Chicago¿¡ À§Ä¡ÇÑ Northwestern ´ëÇÐÀÇ Hirano µîÀÌ Á¦¾ÈÇÑ Adjusted EREFS (Gut 2013)¿¡ ´ëÇÏ¿© van Rhijn BD µîÀÌ external validationÀ» ÇÏ¿´½À´Ï´Ù (Endoscopy 2014). Editorial¿¡´Â È£»ê±¸ ½Äµµ¿°¿¡¼ EREFS systemÀº ¹Ù·¿½Äµµ¿¡¼ Prague systemÀÇ À§Ä¡¿Í ºñ½ÁÇØ Áú °ÍÀ̶ó°í ¾ð±ÞµÇ¾î ÀÖ½À´Ï´Ù.
Adjusted EREFS (Gut 2013, Endoscopy 2014)
Reference pictorial atlas (Gut 2013). (A) Fixed esophageal ring (trachealisation, ringed oesophagus, corrugated oesophagus). (B) Exudates (plaques). (C) Furrows (vertical lines). (D) Edema (decreased vascular markings). (E) Transient oesophageal rings (feline esophagus). (F) Crepe paper esophagus (mucosal fragility).
[ACG Virtual Grand Round (Kathy A Peterson) Facebook ±×¸² (2020-6-26)]
[2015-10-30 ¾Öµ¶ÀÚ ÆíÁö]
Áö¼ÓÀûÀÎ ¼ÒȺҷ®, ¼Ó¾²¸², üÁß °¨¼Ò°¡ ÀÖ´ø ºÐÀÔ´Ï´Ù. ÀÏÀü¿¡ ±³¼ö´Ô²²¼ »çÁøÀ¸·Î º¸¿©Á̴ּø ÀüÇüÀûÀΠȣ»ê±¸¼º ½Äµµ¿°¿¡ ÇÕ´çÇÑ ³»½Ã°æ ¼Ò°ßÀ̾ú°í, Á¶Á÷°Ë»ç¿¡¼ eosinophil 40/HPF ¼Ò°ßÀÌ °üÂûµÇ¾î È£»ê±¸¼º ½Äµµ¿°À» Áø´ÜÇß½À´Ï´Ù. ȯÀںв² Á¦°¡ Ä¡·á °æÇèÀÌ ¾øÀ¸´Ï Å«º´¿ø °¡¼Å¼ Ä¡·áÇϽöó°í Çߴµ¥µµ Àú¿¡°Ô Ä¡·á¹Þ°í ½Í´Ù°í Çϼ̽À´Ï´Ù. Àúº¸°í °øºÎÇؼ Á÷Á¢ Ä¡·áÇØ ´Þ¶ó±¸¿ä. Steroid inhaler ¿ë·®À» ¸ô¶ó¼ °í¹ÎÇß½À´Ï´Ù. PPI ¹× budesonide(PULMICORT TURBUHALER) 2 puff bid ó¹æÇÏ¿´°í Áõ¼¼´Â ´ëºÎºÐ ÁÁ¾ÆÁ³À¸³ª ¼ÒȺҷ®ÀÌ Áö¼ÓµÇ¾ú½À´Ï´Ù. Àα٠º´¿øÀ¸·Î ÀÇ·Úµå·È°í prokinetics Ãß°¡ÇÑ ÈÄ ÁÁ¾ÆÁ³´Ù°í ÇÕ´Ï´Ù.
6. PPI responsive esophageal eosinophilia (PPI-REE) → ´õ ÀÌ»ó »ç¿ëÇÏÁö ¾Ê´Â Áø´Ü¸íÀÔ´Ï´Ù.
È£»ê±¸ ½Äµµ¿°°ú GERDÀÇ »ó°ü°ü°è¿¡ ´ëÇÑ 4°¡Áö ½Ã³ª¸®¿À°¡ ÀÖ½À´Ï´Ù.
PPI responsive esophageal eosinophilia (PPI-REE)´Â °ú°Å EoE Áß PPI ¹ÝÀÀÀÌ ÀÖ´Â °æ¿ì¿¡ »ç¿ëÇÏ´ø ¿ë¾îÀÔ´Ï´Ù. ±×·¯³ª º°µµÀÇ ÁúȯÀ¸·Î °£ÁÖÇÏÁö ¾Ê°í È£»ê±¸ ½Äµµ¿°ÀÇ ¾ÆÇüÀ¸·Î º¸°í ÀÖ½À´Ï´Ù. ±×·¡¼ ¾î ÀÌ»ó »ç¿ëµÇÁö ¾Ê´Â ¿ë¾îÀÔ´Ï´Ù (United European Gastroenterol 2017;5:335) PPI ÀÚü°¡ anti-inflammatory effect°¡ Àֱ⠶§¹®¿¡ ÀϺΠȯÀÚ¿¡¼ PPI response¸¦ º¸ÀÌ´Â °ÍÀ¸·Î Çؼ®µË´Ï´Ù.
2016³â 1¿ùÈ£ Gut and Liver Áö¿¡ ¿¬¼¼´ëÇб³ ¹ÚÈ¿Áø ±³¼ö´Ô²²¼ 6¿¹ÀÇ PPI responsive esophageal eosinophilia (PPI-REE)¸¦ ºÐ¼®ÇÏ ÀڷḦ ¹ßÇ¥Çϼ̽À´Ï´Ù (Jung DH. Gut Liver 2016). 20¸íÀÇ È£»ê±¸ ½Äµµ¿° ȯÀÚ Áß 6¸íÀÌ PPI¿¡ ¹ÝÀÀÀ» º¸¿´´Ù°í ÇÕ´Ï´Ù.
The diagnosis cutoff value for EEI was defined as a peak of ¡Ã15 eosinophils per high-power field (HPF) on esophageal biopsy. Patients were diagnosed with EoE if they met these criteria: (1) presence of symptoms related to esophageal dysfunction; (2) mucosal eosinophilia in a esophageal biopsy with at least 15 eosinophils per HPF, which persisted even after a PPI therapeutic regimen; and (3) absence of other causes of esophageal eosinophilia. Patients were diagnosed with PPI-REE if they had esophageal symptoms and histologic features of esophageal eosinophilia, and resolution of symptoms and histologic features after a 2-month course of a PPI therapeutic regimen.
GERD°¡ ½Äµµ Á¡¸· ¼Õ»óÀ» ÀÏÀ¸Å°¸é EoE¸¦ ¾ÇȽÃų ¼ö ÀÖ½À´Ï´Ù. PPI¸¦ »ç¿ëÇϸé Á¡¸· ¼Õ»óÀÌ È£ÀüµÇ¾î EoEµµ È£ÀüµÉ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼ PPI¸¦ ½á¼ Áõ»óÀÌ ÁÁ¾ÆÁø´Ù°í EoE°¡ ¾Æ´Ï¶ó°í ¸»ÇÒ ¼ö ¾ø½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÌÀ¯·Î ÃÖ±Ù¿¡´Â PPI Ä¡·á¸¦ EoE ¹èÁ¦¸¦ À§ÇÑ °ÍÀ̶ó±âº¸´Ù´Â EoEÀÇ initial treatment·Î ÀÌÇØÇÏ´Â °æÇâÀÔ´Ï´Ù.
EoEÀÇ °³³äÀÌ º¯ÈµÇ°í ÀÖ´Â °ÍÀ» ºÎ»ê´ë À̺ÀÀº ±³¼ö°¡ ±ò²ûÇÏ°Ô Á¤¸®ÇÑ ±×¸²À» º¸¿©ÁØ ÀûÀÌ ÀÖ¾î ¼Ò°³ÇÕ´Ï´Ù.
PPI°¡ µµ¿òµÇ´Â ÀÌÀ¯¿¡ ´ëÇÑ ¼³¸íÀÔ´Ï´Ù.
PPIs have anti-inflammatory effects independent of gastric acid suppression.
PPIs have anti-oxidant properties, inhibition of immune cell function and rection of epithelial cell inflammatory cytokine expression.
[2018-5-14] HpÇÐȸ Áý´ãȸ ¹ÚÈ¿Áø ±³¼ö´Ô Ư° ½Ã Q and A
Áú¹®: ºóµµ´Â ¾î´À Á¤µµÀԴϱî?
´äº¯: Å©·Ðº´°ú ºñ½ÁÇÕ´Ï´Ù.Áú¹®: Á¶Á÷°Ë»ç´Â ¾î¶»°Ô Çմϱî?
´äº¯: ½Äµµ¿¡¼´Â º¸Åë 35cm°ú 25-28cm¿¡¼ Á¶Á÷°Ë»ç¸¦ ÇÕ´Ï´Ù. À§¿¡¼´Â eosinophilic gastritis¸¦ °¨º°Çϱâ À§ÇÏ¿© 2°³ Á¤µµÀÇ reference biopsy¸¦ ÇÕ´Ï´Ù.Áú¹®: Dysphagia¸¦ È£¼ÒÇϴ ȯÀÚ¿¡¼´Â ³»½Ã°æ»ó ÀÌ»ó ¼Ò°ßÀÌ ¾øÀ¸¸é Á¶Á÷°Ë»ç¸¦ ÇØ¾ß Çմϱî?
´äº¯: Æò±Õ 15%¿¡¼ È£»ê±¸ ½Äµµ¿°ÀÌ ³ª¿À±â ¶§¹®¿¡ À°¾È ¼Ò°ßÀÌ Á¤»óÀÌ¶óµµ Á¶Á÷°Ë»ç¸¦ ÇÕ´Ï´Ù.Áú¹®: À½½ÄÁ¦ÇÑÀº ¾î¶»°Ô Çմϱî?
6°³¸¦ ÇÇÇÕ´Ï´Ù. 6 food ȸÇÇ ¿ä¹ýÀ» ±ÇÇÕ´Ï´Ù. (1) ¿ìÀ¯, (2) ¹Ð, (3) °è¶õ, (4) Äá, (5) ¶¥Äá, (6) »ý¼±/Á¶°³. Allergy°¡ °¡Àå °ÇÑ °ÍÀÌ ¿ìÀ¯, °¡Àå ¾àÇÑ °ÍÀÌ »ý¼±/Á¶°³ÀÔ´Ï´Ù.Áú¹®: Ä¡·á ÈÄ ½Äµµ º´º¯Àº È£ÀüµË´Ï±î?
´äº¯: Furrow (edema)°¡ °³¼±µÇ°í ring(subepithelial fibrosis)Àº ³²½À´Ï´Ù.Áú¹®: EoE¿Í PPI-REEÀÇ °ü°è´Â ¾î¶»½À´Ï±î?
´äº¯: EoE¿Í PPI-REE´Â ÀÓ»óÀûÀ¸·Î °ÅÀÇ ±¸ºÐÇϱ⠾î·Æ½À´Ï´Ù. PPI-REE´Â EoEÀÇ ÇÑ subtype Á¤µµ·Î °£Áֵǰí ÀÖ½À´Ï´Ù.Áú¹®: EoEÀÇ subtypeÀº ¹«¾ùÀԴϱî?
´äº¯: Fibrotic disease¿Í inflammatory disease·Î ³ª´©¾îÁý´Ï´Ù.Áú¹®: ³»½Ã°æÀûÀ¸·Î ÀǽɵǴ ȣ»ê±¸ ½Äµµ¿°ÀÇ Àǹ̴Â?
´äº¯: ³»½Ã°æÀûÀ¸·Î ÀǽɵǴ ȣ»ê±¸ ½Äµµ¿° ȯÀÚµéÀÇ °æ¿ì, ½ÇÁ¦ È£»ê±¸ ½Äµµ¿°À¸·Î Áø´ÜµÇ´Â Áø´Ü ÀÏÄ¡µµ´Â ¾à 29.4%¿´À¸¸ç, ESEoS ȯÀÚµé Áß '»ïÅ´°ï¶õÀÇ Áõ»ó', '»ïÃâ¹° ¹× °áÀýÀÌ ÀÖ´Â °æ¿ì', '2°¡Áö ÀÌ»óÀÇ ³»½Ã°æ ¼Ò°ßÀ» µ¿½Ã¿¡ º¸ÀÎ °æ¿ì'°¡ EoE ±º°ú EoE- ±º °£¿¡ Åë°èÀûÀ¸·Î ÀǹÌÀÖ´Â Â÷À̸¦ º¸¿´´Ù. (Korean J Gastroenterol 2010;56:285-292)Áú¹®: ¼Ò¾Æ EoEÀÇ Áõ»óÀº ¾î¶°Çմϱî?
´äº¯: 12¼¼ ¹Ì¸¸¿¡¼´Â ¼ºÀåÀå¾Ö emesis, vomiting, food refusalÀ» º¸ÀÔ´Ï´Ù. Ä¿°¡¸é¼ 13¼¼ ÀÌÇÏ¿¡¼ dysphagia, food impaction µîÀÌ ³ªÅ¸³³´Ï´Ù.Áú¹®: ¾î¶² °æ¿ì¿¡ À¯Áö¿ä¹ýÀ» Çմϱî?
´äº¯: The expert consensus opinion is that evidence of chronic remodelling, as in patients with long strictures or a small-caliber esophagus, a history of food impactions or severe symptoms, or rapid recurrence of illness while not receiving therapy, indicate the need for maintenance therapy. (Dellon ES, 2013)
[2015-12-10. ¾Öµ¶ÀÚ Áú¹®]
20´ë ³²ÀÚ È¯ÀÚ·Î ¿¬ÇÏ°ï¶õÀ» ÁÖ¼Ò·Î ³»¿øÇÏ¿© À§³»½Ã°æÀ» ½ÃÇàÇß½À´Ï´Ù. ³»½Ã°æ »çÁø¿¡¼´Â È£»ê±¸¼º ½Äµµ¿° ÀǽɵǾú°í, ÀÌ¿¡ Á¶Á÷ °Ë»ç ½ÃÇàÇÏ¿´½À´Ï´Ù. °Ë»ç °á°ú´Â >15/HPF ÀÌ»óÀÇ È£»ê±¸ °üÂûµÇ¾î eosinophilic esophagitis·Î Áø´ÜµÈ »óÅÂÀÔ´Ï´Ù. ¿øÀÎ Ç׿øÀ» ¾Ë±â À§ÇÏ¿© MAST (ÀúÈñ º´¿ø¿¡¼´Â 30Á¾À¸·Î µÈ food MAST °Ë»ç°¡ ÀÖ½À´Ï´Ù) ¹× IgE °Ë»ç ½ÃÇà ÈÄ Ä¡·áÁ¦·Î fluticasone, budesonide¸¦ »ç¿ëÇÏ·Á ÇÏ¿´½À´Ï´Ù. ÇÏÁö¸¸ fluticasoneÀº seretide (salmeterol Æ÷ÇÔ)·Î õ½Ä ¶§ »ç¿ëµÇ´Â ÈíÀÔÁ¦¸¸ ÀÖ°í budesonideµµ ÈíÀÔÁ¦(symbicort, ÈíÀÔ ¶§ »ç¿ëÇÏ´Â budesonide solution)¸¸ ÀÖ´Â »óÅÂÀÔ´Ï´Ù. À̹ø¿¡ NEJMÀÇ review¸¦ ÀÐ°í ¾àÁ¦¸¦ »ç¿ëÇÏ·Á´Ù°¡ ¾àÁ¦°¡ ¾ø´Â °ü°è·Î °í¹ÎÇÏ´Ù MAST °Ë»ç °á°ú º¸°í Ä¡·á ½ÃÀÛÇÏÀÚ°í ȯÀÚ¿¡°Ô À̾߱âÇØ ³õÀº »óÅÂÀÔ´Ï´Ù. Ȥ½Ã ÈíÀÔÁ¦¸¦ Ä¡·áÁ¦(ÈíÀÔ ÈÄ »ïÅ´)·Î ½áµµ µÇ´ÂÁö, ¾Æ´Ï¸é º´¿ø »çÁ¤»ó solondo¸¦ ½á¼ Ä¡·áÇصµ µÇ´ÂÁö, ±³¼ö´Ô²²¼´Â ¾î¶»°Ô Ä¡·áÇϽôÂÁö ±Ã±ÝÇÕ´Ï´Ù. ±×¸®°í È£»ê±¸¼º ½Äµµ¿°ÀÌ Áø´ÜµÇ¸é ±³¼ö´Ô²²¼´Â ¹«½¼ °Ë»ç¸¦ ÇϽôÂÁöµµ ¾Ë°í ½Í½À´Ï´Ù.
[2015-12-14. ÀÌÁØÇà ´äº¯]
»ç½Ç Á¦°¡ Ä¡·áÇÏ°í Àִ ȣ»ê±¸½Äµµ¿° ȯÀÚ´Â ¾ø½À´Ï´Ù. ÀǽɵǸé motility part ¼±»ý´Ô²² ÀÇ·ÚÇÏ°í ÀÖ½À´Ï´Ù. Á¦°¡ ¾Ë±â·Î´Â óÀ½¿¡´Â ÀÏ´Ü PPI¸¦ ½áº¸°í ¹ÝÀÀÀÌ ¾øÀ¸¸é steroid inhaler puff¸¦ »ç¿ëÇÕ´Ï´Ù (ÈíÀÔÇÏÁö ¸»°í »ïÅ°µµ·Ï ÇÕ´Ï´Ù). ´ëÇѼÒȱâÇÐȸÁö(2010;56:285-292)¿¡ ½Ç¸° ¿¬¼¼´ëÇб³ °³²¼¼ºê¶õ½ºº´¿ø ¹ÚÈ¿Áø ±³¼ö´ÔÀÇ Áõ·Ê¸¦ º¸¸é "Á¤·®½Ä ÈíÀÔ±â(metered dose inhaler, MDI)¸¦ ÀÌ¿ëÇÑ ±¹¼Ò ½ºÅ×·ÎÀ̵å ÈíÀοä¹ý(fluticasone inhaler 125 ug/puff, 1,000 ug/D for 4 weeks)À» ½ÃÇàÇÏ¿´´Ù"°í ±â¼úµÇ¾î ÀÖ½À´Ï´Ù. ¹ÚÈ¿Áø ±³¼ö´ÔÀÇ 2007³â Á¾¼³¿¡´Â inhaler »ç¿ë¹ýÀ» "After shaking the inhaler, take a deep breath. At the point of maximum held inspiration, depress the inhaler and swallow the aerosol with each puff"·Î ¼³¸íÇÏ°í °è½Ê´Ï´Ù. Ã¥¿¡´Â fluticasoneÀÌ ÁÖ·Î ¾ð±ÞµÇ°í ÀÖÁö¸¸ ÇöÀå¿¡¼´Â budesonideµµ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¾Æ·¡ 2015³â NEJM ¸®ºä table¿¡¼ budesonide¸¦ º¸½Ç ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù. NEJM¿¡¼´Â ¿ì¸®´Â ¾µ ¼ö ¾ø´Â oral viscous budesonide¸¦ ¾ð±ÞÇÏ°í ÀÖ½À´Ï´Ù. Àü½Å ½ºÅ×·ÎÀ̵带 »ç¿ëÇÒ ¼öµµ Àִµ¥ ºÎÀÛ¿ë ¿ì·Á¶§¹®¿¡ °¡±ÞÀû steroid inhaler¸¦ »ç¿ëÇϸé ÁÁ½À´Ï´Ù. ¸î °¡Áö °Ë»ç¸¦ ÅëÇÏ¿© À½½Ä¹° Á¾·ù¸¦ Á¦ÇÑÇÏ´Â Àü·«Àº Å©°Ô È¿°úÀûÀÌÁö ¾ÊÀº °Í °°½À´Ï´Ù. Àú´Â ¾Ë·¹¸£±â ³»°ú¿¡ ÀÇ·ÚÇÏ¿© °Ë»ç¹Þµµ·Ï Á¶Ã³ÇÏ°í ÀÖ½À´Ï´Ù.
[2015-12-11. »ï¼º¼¿ïº´¿ø ¹Î¾ç¿ø ±³¼ö´Ô ´äº¯]
È£»ê±¸ ½Äµµ¿° ±¹³» ÄÉÀ̽º°¡ ¸¹Áö ¾Ê¾Æ ¿ì¸®º´¿ø ÀÚü ÇÁ·ÎÅäÄÝÀº ¾ø½À´Ï´Ù. PPI Ä¡·á¸¦ ¸ÕÀúÇÏ°í ¹ÝÀÀÀÌ ¾øÀ¸¸é ¾Ë·¹¸£±â ³»°ú·Î º¸³» ¾Ë·¹¸£±â °Ë»ç¿Í ½ºÅ×·ÎÀ̵å Ä¡·á¸¦ ¹Þµµ·Ï ÇÕ´Ï´Ù. È£»ê±¸ ½Äµµ¿°À̶ó°í »ý°¢ÇÏÁö¸¸ ½ÇÁ¦·Î´Â GERD ¿Í ¿¬°üµÈ esophageal eosinophilia ¸¦ º¸ÀÌ´Â °æ¿ì°¡ ÀûÁö ¾ÊÀ¸¹Ç·Î, PPI Ä¡·á¸¸À¸·Îµµ Áõ»óÈ£ÀüÀÌ °¡´ÉÇϱ⠶§¹®¿¡ (PPI responsive esophageal eosinophilia) PPI Ä¡·á¸¦ ¸ÕÀúÇÕ´Ï´Ù. È£»ê±¸ ½Äµµ¿°¸¦ Æ÷ÇÔÇÑ eosinophilic GI disorders¿¡ ´ëÇÑ ¾Ë·¹¸£±â °Ë»ç¹ý ¹× Ä¡·á¹ý Á¤¸³ÀÌ ÇÊ¿äÇÒ °ÍÀ¸·Î »ý°¢µÇ¾î ¾Ë·¹¸£±â ³»°ú ±³¼ö´Ô²² »óÀÇ ÁßÀÔ´Ï´Ù.
[2016-12-5. ûÁÖ¿¡¼ ¾Öµ¶ÀÚ Áú¹®]
¾È³çÇϼ¼¿ä, ÀÌÁØÇà ±³¼ö´Ô. °ËÁø¼¾ÅÍ¿¡¼ ÁÖ·Î »ó´ãÀ» ´ã´çÇÏ°í ÀÖ´Â ÀÇ»çÀÔ´Ï´Ù. ³»½Ã°æ °Ë»ç¸¦ Á÷Á¢ ¼öÇàÇÏÁö´Â ¾ÊÁö¸¸, ¼ö°ËÀÚ¿¡°Ô ³»½Ã°æ ¼Ò°ß°ú »çÈÄ °ü¸®¿¡ ´ëÇØ ¼³¸íµå¸± ¶§ EndoTODAY¿¡¼ ¸¹Àº µµ¿òÀ» ¹Þ°í ÀÖ½À´Ï´Ù. °¨»çÇÕ´Ï´Ù.^^
È£»ê±¸ ½Äµµ¿°°ú °ü·ÃµÈ ³»¿ëÀ» ÀÐÀ¸¸é¼ ½ºÅ×·ÎÀÌµå ±¹¼Ò ¿ä¹ý°ú °ü·ÃµÈ ±Ã±ÝÁõÀÌ »ý°Ü ¸ÞÀÏÀ» ¿Ã¸³´Ï´Ù. The ¡®skinny¡¯ on eosinophilic esophagitis¶ó´Â ³í¹®¿¡ ¾Æ·¡¿Í °°Àº ³»¿ëÀÌ ÀÖ½À´Ï´Ù.
"Topical therapy is showing promise as both a short- and long-term option to bring about remission. For administration, a corticosteroid (budesonide or fluticasone) is mixed with a viscous solution, such as water with honey or chocolate syrup, making it thick so it better coats the esophagus."
ÀÌ ¹®ÀåÀ» ÀÐ°í »ý°¢³ ±Ã±ÝÁõÀº ÀÌ°Ì´Ï´Ù. ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ºÐ¹«¿ë ÇöŹ¾×(Ç®¹ÌÄ, Èĸ¯¼ÒŸÀ̵å)ÀÌ Àִµ¥, ÀÌ ÇöŹ¾×À» ¹°/²Ü°ú È¥ÇÕÇÏ¿© È£»ê±¸½Äµµ¿° ȯÀÚ¿¡°Ô º¹¿ë½Ãų ¼ö ÀÖÀ»±î¿ä? ±¹¼Ò¿ä¹ýÀÌ È¿°úÀûÀ̶ó°í Çϴµ¥, »óÇ°ÈµÈ Á¦Ç°ÀÌ ±¹³»¿¡ ¾ø´Â °Í °°¾Æ ±Ã±ÝÁõÀÌ ¹ßµ¿Çß½À´Ï´Ù.^^
[2016-12-6. ÀÌÁØÇà ´äº¯]
¾È³çÇϽʴϱî. Áú¹®ÀÇ ³»¿ëÀº Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù¸¸, Á¦°¡ È®½ÇÇÑ ´äº¯À» µå¸®±â´Â ¾î·Æ½À´Ï´Ù. Çѹøµµ ó¹æÇØ º» ÀûÀÌ ¾ø±â ¶§¹®ÀÔ´Ï´Ù.
ºÐ¹«¿ë ÇöŹ¾×À» ±×³É »ïÅ°µµ·Ï ÇÏ´Â °ÍÀº ¸ô¶óµµ ²Ü¹°À̳ª ÃÊÄÚ·¿ ½Ã·´¿¡ Ÿ¼ ¸Ô´Â °ÍÀº.... ³í¶õÀÇ ¿©Áö°¡ ÀÖ´Ù°í º¾´Ï´Ù. ¾Æ½Ã´Ù½ÃÇÇ ºÐ¹«¿ë ½ºÅ×·ÎÀ̵å´Â »ó´ç ºÎºÐ ½Äµµ·Î ³Ñ¾î°©´Ï´Ù. ¾Æ¹«¸® ÈíÀÔÇÏ·Á°í ³ë·ÂÇصµ »ïÄÑÁö´Â ºÎºÐÀÌ ¸¹½À´Ï´Ù. µû¶ó¼ °æ±¸ ¼·Ã븦 À§ÇÏ¿© ²Ü¹° µîÀ» µ¿¿øÇÒ ÇÊ¿ä´Â ¾ø¾î º¸ÀÔ´Ï´Ù.
È£»ê±¸ ½Äµµ¿°Àº ¿ì¸®³ª¶ó¿¡¼´Â ¾ÆÁ÷ Èñ±ÍÁúȯ¿¡ ¼ÓÇÕ´Ï´Ù. Àü¹®°¡¿¡°Ô ÀÇ·Ú¸¦ ÇÏ´Â °ÍÀÌ ÁÁÀ» °Í °°½À´Ï´Ù. ÀúÈñ º´¿ø¿¡¼´Â ¹Î¾ç¿ø ±³¼ö´Ô, ¿¬¼¼´ë º´¿ø¿¡¼´Â ¹ÚÈ¿Áø ¼±»ý´Ô µîÀÌ °¡Àå Àü¹®°¡À̽ʴϴÙ. ½Ã¿øÇÑ ´äº¯ µå¸®Áö ¸øÇØ Á˼ÛÇÕ´Ï´Ù.
[¹«Áõ»ó È£»ê±¸ ½Äµµ¿°. asymptomatic eosinophilic esophagitis]
[2017-1-3. ¾Öµ¶ÀÚ Áú¹®]
À̹ø¿¡ óÀ½À¸·Î eosinophilic esophagitis·Î Áø´ÜµÈ ºÐÀÔ´Ï´Ù. Ư¡ÀûÀÎ ¼Ò°ßÀÌ º¸¿© Á¶Á÷°Ë»ç¸¦ ÇÏ¿´°í eosinophilÀÌ HPF »ó 34°³ °üÂûµÇ¾ú°í Ç÷¾×°Ë»ç¿¡¼ È£»ê±¸°¡ 11.8%¿´½À´Ï´Ù.
¹®Á¦´Â À̺ÐÀÌ ±×¸® ºÒÆíÇÑ Áõ»óÀÌ ¾ø´Ù´Â Á¡ÀÔ´Ï´Ù. »ì¦ »ïų¶§ ºÒÆíÇÑ Áõ»óÀÌ ÀÖÀ¸³ª ¹Ù·Î ¹°À» ¸¶½Ã¸é ±¦Âú¾ÆÁ®¼ Ä¡·á°¡ ÇÊ¿ä¾ø´Ù°í ´À³¢´Â ºÐÀÔ´Ï´Ù. Á¦ »ý°¢¿£ referÇÏ¿© ½ºÅ×·ÎÀ̵å inhaler Ä¡·á¸¦ »ý°¢Çߴµ¥, ºÒÆíÇÑ Áõ»óÀÌ ¾ø´Â ºÐÀ̶ó¸é Àû±ØÀûÀÎ Ä¡·á¸¦ ±ÇÇÏÁö ¾Ê¾Æµµ µÇ´Â °É±î ±Ã±ÝÇؼ ¸ÞÀÏ ¿Ã¸³´Ï´Ù.
[2017-1-3. ÀÌÁØÇà ´äº¯]
Áõ»óÀ» ´Ù½Ã Çѹø Àß ¹°¾îº¸´Â °Íµµ ÁÁÀ» °Í °°½À´Ï´Ù. Eosinophilic esophagitis °°±â´Â Çѵ¥... PPI responsive esophageal eosinophilia (PPI-REE)¶ó´Â °Íµµ °í·ÁÇØ¾ß ÇϹǷΠ¾ÆÁÖ Áõ»óÀÌ ½ÉÇÏÁö ¾Ê´Â ÇÑ Ã³À½ºÎÅÍ steroid¸¦ ¾²Áö ¾Ê°í ¸î ÁÖ°£ PPI¸¦ ½á¼ Áõ»óÀÇ º¯È¸¦ º¸´Â °ÍÀÌ º¸ÅëÀÔ´Ï´Ù. È£ÀüµÇ¸é ±×¸¸ÀÌÁö¸¸, È£ÀüµÇÁö ¾ÊÀ¸¸é ±× ¶§ steroid »ç¿ëÀ» °í·ÁÇÏ¸é µÉ °Í °°½À´Ï´Ù. [2018-12-14. ÀÌÁØÇà ñÉ: PPI-REE´Â ´õ ÀÌ»ó »ç¿ëµÇÁö ¾Ê´Â ¿ë¾îÀÔ´Ï´Ù.]
[2018-12-13. ¾Öµ¶ÀÚ Áú¹®]
¹«Áõ»ó ³²ÀÚ 40¼¼ÀÇ °ËÁø ³»½Ã°æÀÔ´Ï´Ù. ÇϺνĵµ¿¡ longitudinal ÇÏ°Ô ±æ°Ô °í¶ûó·³ ÆÄ¿©ÀÖ´Â ¼Ò°ßÀÌ °üÂûµÇ¾ú½À´Ï´Ù.
È£»ê±¸¼º ½Äµµ¿°ÀÌ ÀÌ·¸°Ô º¸ÀÎ´Ù°í ¹è¿ü´ø°Í °°Àºµ¥¿ä... ¹«Áõ»ó °ËÁø ³»½Ã°æ¿¡¼, ÀÌ·± ¼Ò°ßÀÌ °üÂûµÇ¸é, ¾î¶»°Ô óġÇØ¾ß ÇÏ´ÂÁö¿ä? Biopsy ¸¦ ÇؾßÇÏ´ÂÁö¿ä?
[2018-12-14. »ï¼º¼¿ïº´¿ø ¹Î¾ç¿ø ±³¼ö´Ô ´äº¯]
Rings, furrows°¡ ÇÔ²² ÀÖ´Â ÀüÇüÀûÀÎ EoE ³»½Ã°æ ¸ð¾çÀÔ´Ï´Ù. ±×·¡µµ ¿ì¼±ÀûÀ¸·Î Á¶Á÷°Ë»ç¸¦ ÅëÇØ È®Áø(Eosinophil >15/HPF)À» ³»¸®´Â °ÍÀÌ ÇÊ¿äÇÏ°Ú½À´Ï´Ù. EoE Ä¡·á´Â Áõ»óÇØ¼Ò¿Í Á¶Á÷ÇÐÀû °üÇØ µÎ °¡Áö¸¦ ¸ñÇ¥·Î ½ÃÇàµÇ´Âµ¥ ¹«Áõ»ó »óÅ¿¡¼µµ ¿°ÁõÀÌ ÁøÇàµÇ¾î ÇùÂøÇü(stenotic)À¸·Î ¹ßÀüÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù.
¹«Áõ»ó EoE Ä¡·á¿¡ ´ëÇÑ consensus ´Â ¾øÁö¸¸ ÀÌÁ¦±îÁö ¾Ë·ÁÁø ÀÚ¿¬°æ°ú(¸¸¼º, ÁøÇà)¸¦ °í·ÁÇϸé PPI (´ÙÀ½À¸·Î´Â topical steroid »ç¿ë °¡´É) Ä¡·á·Î °üÇظ¦ À¯µµÇØ¾ß ÇÒ °Í °°½À´Ï´Ù (º´¸®ÇÐÀû eosinophilia ÇؼÒ). ÀÌÈÄ·Î Á¤±âÀû ÃßÀû °üÂûÀ» ÇÏ¸é¼ Àç¹ßÇÏÁö ¾Ê´ÂÁö »ìÆì¾ß ÇÒ °Í °°½À´Ï´Ù (»ïÅ´°ï¶õ, °¡½¿¾²¸², °¡½¿ÅëÁõ°ú °°Àº Áõ»ó Àç¹ß ¶Ç´Â ½Äµµ³» eosinophilic infiltration ¹ß»ý).
[2018-7-26. ¹Î¾ç¿ø ±³¼ö´Ô Ư°]
Áú¹®: Systemic disease·Î º¸½Ã³ª¿ä, organ specific disease·Î º¸½Ê´Ï±î?
´äº¯: Systemic involvement°¡ ÀÖÀ¸¸é definition¿¡ ÀÇÇÏ¿© EoE¿¡¼ ºüÁý´Ï´Ù. Systemic involvement°¡ ÀÖ°í Áõ»óÀÌ ÀÖÀ¸¸é oral steroid¸¦ ¾²°í ÀÖ½À´Ï´Ù.
Áú¹®: ù Ä¡·á·Î PPI¸¦ ½áº¼ ¼ö ÀÖ´Ù°í Çϼ̴µ¥¿ä... ¾î¶² ¾àÀ» ÃßõÇϽʴϱî? ¾àÁ¦¸¶´Ù anti-inflammatory effect°¡ ´Ù¸¦ °Í °°±â ¶§¹®ÀÔ´Ï´Ù.
´äº¯: ¸®ºä¿¡¼´Â Brand´Â »ó°ü¾ø´Ù°í µÇ¾î ÀÖ½À´Ï´Ù. "Equivalent PPI can be administered." (NEJM 2015;373:1640-1648)
Áú¹®: Food impaction·Î ÀÀ±Þ½Ç·Î ³»¿øÇÑ È¯ÀÚ¿¡¼ ³»½Ã°æÀ¸·Î °í±â µ¢¾î¸®¸¦ Á¦°ÅÇÑ ÈÄ ±× ³¯ Áï½Ã Á¶Á÷°Ë»ç¸¦ ÇÒ ÇÊ¿ä°¡ ÀÖ½À´Ï±î?
´äº¯: EoE°¡ food impactionÀ» ÀÏÀ¸Å³ Á¤µµ¸é mucosal lesionÀÌ ÀÖÀ» °Í °°½À´Ï´Ù.
[2021-11-7. ¿îµ¿ÇÐȸ ½ÉÆ÷Áö¾ö Á¤±â¿í ±³¼ö´Ô °ÀÇ] PPI°¡ Eotaxin-3¸¦ °¨¼Ò½ÃŲ´Ù. P-CABµµ ºñ½ÁÇÑ È¿°ú°¡ ÀÖ´Ù (Gastroenterology 2021). ½Äµµ Á¶Á÷ È£»ê±¸ÁõÀº ¾øÀ¸³ª Áõ»óÀº ºñ½ÁÇÑ EoE-like disease°¡ ¾ð±ÞµÇ°í Àִµ¥ lymphocytic esophagitis°¡ ±× Áß ÇϳªÀÌ´Ù. EoE¿Í achalasiaÀÇ °ü°è¿¡ ´ëÇÑ ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ´Ù.
[2023-1-22. KSGE webinar ±è°¡Èñ ±³¼ö´Ô °ÀÇ]
[2024-4-30. Helicobacter ÇÐȸ Áý´ãȸ]
EoE´Â heterogenous groupÀÌ´Ù.
ÀþÀº ȯÀÚ¿¡¼´Â ½ÉÇÑ Áõ»óÀÌ ¸¹À¸³ª ÁßÀå³â ÀÌÈÄ¿¡´Â ½ÉÇÑ °æ¿ì°¡ µå¹°´Ù.
ÇѹøÀÇ episode ÈÄ Àç¹ß ¼Ò°ßÀÌ ¾ø´Â ȯÀÚ°¡ 20% Á¤µµ ÀÖ´Ù.
°í·ÉÀÇ ¹«Áõ»ó EoE¿¡¼´Â ±ÞÈ÷ Ä¡·á°¡ ÇÊ¿äÇÏÁö ¾ÊÀ» ¼ö ÀÖ´Ù.
[2024-8-13. SMC È¿ä³»½Ã°æÁý´ãȸ]
1) È£»ê±¸½Äµµ¿° Á¾¼³ ¹ÚÈ¿Áø. ¼ÒȱâÇÐȸÁö 2007
3) How I Approach the Management of Eosinophilic Esophagitis in Adults - Ikuo Hirano Am J Gastroenterol 2017. PDF 0.5M
4) AGA patient education section
5) 2020-8-3 AGC Education Universe
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼ÒÀÌÁØÇà EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.